NYMC Faculty Publications
Use of Levosimendan in Acute and Advanced Heart Failure: Short Review on Available Real-World Data
Journal Title
Therapeutics and Clinical Risk Management
First Page
765
Last Page
772
Document Type
Article
Publication Date
June 2019
Department
Medicine
Abstract
Published data have shown potential advantages of levosimendan in the management of acute decompensated heart failure and advanced heart failure when standard medical therapies threaten hemodynamics and organ perfusion are unable to alleviate clinical symptoms. Levosimendan distinguishes itself from other catecholaminergic inotropes by its three mechanisms of action: positive inotropy, vasodilation, and cardioprotection. In addition, its pharmacokinetics allow for a longer duration of action from the metabolite OR1896 allowing for further cardiovascular therapeutic effects for several days, even after discontinuation of the parent drug.
Recommended Citation
Pashkovetsky, E., Gupta, C. A., & Aronow, W. (2019). Use of Levosimendan in Acute and Advanced Heart Failure: Short Review on Available Real-World Data. Therapeutics and Clinical Risk Management, 15, 765-772. https://doi.org/10.2147/TCRM.S188761
